LFMDHIGH SIGNALOPERATIONAL10-K

LFMD divested its WorkSimpli subsidiary in November 2025, which contributed to a dramatic financial turnaround including swinging from -$18.9M to +$14.4M net income and transforming stockholders' equity from negative $5.5M to positive $23.2M.

The divestiture of WorkSimpli represents a strategic refocusing on core telehealth operations, as evidenced by updated language emphasizing "patient-centric, direct-to-patient healthcare" versus the previous broader "direct-to-patient telehealth" positioning. The sale appears to have eliminated problematic assets or liabilities, enabling the company to achieve profitability and significantly strengthen its balance sheet, though operating cash flow declined substantially suggesting the earnings improvement may include one-time gains from the transaction.

Comparing 2026-03-10 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

LFMD experienced a remarkable financial transformation with net income swinging positive by $33.3M to achieve $14.4M profit, while revenue grew a strong 49.8% to $12.5M and stockholders' equity turned positive by $28.7M. The balance sheet strengthened significantly with total liabilities declining 38.2% and interest expense falling 37.6%, though operating cash flow dropped sharply by 52.7% to $8.3M despite the profitability improvement. The divergence between strong earnings and weaker operating cash flow, combined with the WorkSimpli divestiture, suggests the financial turnaround may be partly driven by one-time gains rather than purely operational improvements.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+522.1%
-$5.5M$23.2M

Equity base grew 522.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Share Buybacks
Cash Flow
+252.3%
$77K$270K

Share repurchases increased 252.3% — management returning capital, signals confidence in intrinsic value.

Net Income
P&L
+176%
-$18.9M$14.4M

Net income grew 176% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
-52.7%
$17.5M$8.3M

Operating cash flow fell 52.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Operating Income
P&L
+52.5%
-$16.1M-$7.7M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Revenue
P&L
+49.8%
$8.3M$12.5M

Strong top-line growth of 49.8% — accelerating demand or successful expansion into new markets.

Total Liabilities
Balance Sheet
-38.2%
$76.5M$47.3M

Liabilities reduced 38.2% — deleveraging improves balance sheet strength and financial flexibility.

Interest Expense
P&L
-37.6%
$2.2M$1.4M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Current Liabilities
Balance Sheet
-31%
$60.3M$41.6M

Current liabilities reduced — improved short-term financial position and working capital health.

Capital Expenditure
Cash Flow
+25.5%
$1.5M$1.9M

Capex increased 25.5% — ongoing investment in capacity or infrastructure for future growth.

LANGUAGE CHANGES
NEW — 2026-03-10
PRIOR — 2025-03-11
ADDED
Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission ( SEC ).
(formerly known as Conversion Labs, Inc.), and LifeMD Pharmacy Holdings LLC, an affiliated limited liability company, ( LifeMD Pharmacy ).
On November 4, 2025, we sold our interest in our majority-owned subsidiary WorkSimpli Software LLC (formerly known as LegalSimpli Software, LLC), a Puerto Rico limited liability company ( WorkSimpli ) to Lion Buyer, LLC.
WorkSimpli is classified as discontinued operations for all periods presented in these consolidated financial statements included in this Annual Report on Form 10-K.
BUSINESS Business Overview LifeMD is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services.
+7 more — sign up free →
REMOVED
Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission ( SEC ), including the risk factors identified in Item 1A of this report.
(formerly known as Conversion Labs, Inc.), LifeMD Pharmacy Holdings LLC, an affiliated limited liability company, ( LifeMD Pharmacy ) and our majority-owned subsidiary WorkSimpli Software LLC (formerly known as LegalSimpli Software, LLC), a Puerto Rico limited liability company ( WorkSimpli ).
BUSINESS Business Overview We are a direct-to-patient telehealth company providing a high-quality, cost-effective, and convenient way to access comprehensive, virtual and in-home healthcare.
We believe the traditional model of visiting a doctor s office, traveling to a retail pharmacy, and returning for follow-up care or prescription refills is complex, inefficient, and costly which discourages many individuals from seeking much-needed medical care.
LifeMD is improving the delivery of the healthcare experience through telehealth with our proprietary technology platform, affiliated and dedicated provider network, broad and expanding treatment capabilities, and the unique ability to nurture patient relationships.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →